TrialRMD open2019

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.